Adamaspharma
Acquired2 known investors
A biopharmaceutical company with over 30 years of experience developing and commercializing treatments for central nervous system (CNS) diseases. It maintains a pipeline of product candidates supported by internal research and development.
Also known as Adamas Pharmaceuticals
Investors · 2
Company profile
researched Aug 2026The adamaspharma.com domain currently serves the corporate website of Supernus Pharmaceuticals, a biopharmaceutical company that describes itself as having more than 30 years of experience developing and commercializing products treating central nervous system (CNS) diseases. Supernus states that research and development are central to its operations and maintains a pipeline of product candidates alongside marketed products spanning several therapeutic categories aimed at patients with CNS conditions.
The site also functions as an information hub for acquired businesses: it notes that Sage Therapeutics was acquired by Supernus Pharmaceuticals and routes visitors to Sage-related resources for funding and giving, medical affairs, and whistleblower reporting, as well as to Supernus Medical Information Support for adverse event and product complaint reporting. Additional sections cover investor relations, careers, and a resource center for patients and healthcare providers, and the site promotes the approval of the product QELBREE with links to prescribing information and a medication guide.
▸Full profile — technology, go-to-market
Technology
Product development is centered on therapies for central nervous system diseases, supported by internal research and development activity and a pipeline of product candidates described on the company website [0].
Go-to-market
Patients living with CNS diseases and the healthcare providers who treat them, with dedicated resource sections for both groups [0].
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsThe website hosted at adamaspharma.com states that Sage Therapeutics was acquired by Supernus Pharmaceuticals and provides successor contact points for Sage information.
A site notice announces that QELBREE is approved, linking to a press release, prescribing information including a boxed warning, and a medication guide.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Adamaspharmaadamaspharma.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Adamaspharma do?
- Biopharmaceutical business whose website now resolves to Supernus Pharmaceuticals, a developer of CNS disease treatments.
- Who are Adamaspharma's investors?
- Adamaspharma's investors include BioBrit, Dag Ventures.